WO2010077101A3 - 신규한 티아졸리딘디온 유도체 및 그의 용도 - Google Patents
신규한 티아졸리딘디온 유도체 및 그의 용도 Download PDFInfo
- Publication number
- WO2010077101A3 WO2010077101A3 PCT/KR2009/007995 KR2009007995W WO2010077101A3 WO 2010077101 A3 WO2010077101 A3 WO 2010077101A3 KR 2009007995 W KR2009007995 W KR 2009007995W WO 2010077101 A3 WO2010077101 A3 WO 2010077101A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiazolidinedione derivative
- novel thiazolidinedione
- chemical formula
- following chemical
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117017782A KR101172638B1 (ko) | 2008-12-30 | 2009-12-30 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
EP09836422.7A EP2383263B1 (en) | 2008-12-30 | 2009-12-30 | Novel thiazolidinedione derivative and use thereof |
US13/142,924 US8637558B2 (en) | 2008-12-30 | 2009-12-30 | Thiazolidinedione derivative and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0136921 | 2008-12-30 | ||
KR20080136921 | 2008-12-30 | ||
KR20090055326 | 2009-06-22 | ||
KR10-2009-0055326 | 2009-06-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010077101A2 WO2010077101A2 (ko) | 2010-07-08 |
WO2010077101A3 true WO2010077101A3 (ko) | 2010-10-21 |
WO2010077101A4 WO2010077101A4 (ko) | 2011-01-13 |
Family
ID=42310414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007995 WO2010077101A2 (ko) | 2008-12-30 | 2009-12-30 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8637558B2 (ko) |
EP (1) | EP2383263B1 (ko) |
KR (1) | KR101172638B1 (ko) |
WO (1) | WO2010077101A2 (ko) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2870666A1 (en) | 2012-04-16 | 2013-10-24 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
US9261497B2 (en) | 2012-10-16 | 2016-02-16 | New York University | Method of treating cancer with modulators of SCFSkp2 |
AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
EP3267995A4 (en) | 2015-03-08 | 2019-02-27 | Case Western Reserve University | INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF FIBROSIS |
CA2982784A1 (en) * | 2015-04-14 | 2016-10-20 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
LT3325482T (lt) * | 2015-07-21 | 2020-11-25 | Immunogen, Inc. | Citotoksinių benzodiazepino darinių paruošimo būdai |
KR101843927B1 (ko) * | 2015-10-27 | 2018-03-30 | 주식회사 이에이치엘바이오 | 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도 |
WO2017074043A1 (ko) * | 2015-10-27 | 2017-05-04 | 주식회사 이에이치엘바이오 | 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도 |
KR101817287B1 (ko) | 2016-01-08 | 2018-01-10 | 조선대학교 산학협력단 | 티아졸리딘디온 유도체 및 그의 용도 |
DK3439667T3 (da) * | 2016-04-05 | 2024-04-02 | Immune Sensor Llc | Cgas antagonist forbindelser |
WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
WO2018187810A1 (en) * | 2017-04-07 | 2018-10-11 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
KR101912142B1 (ko) * | 2018-01-04 | 2018-10-29 | 주식회사 이에이치엘바이오 | 15-pgdh 억제제를 처리한 세포 또는 그것의 배양물을 포함하는 조성물과 그의 용도 |
JOP20210115A1 (ar) | 2018-11-21 | 2023-01-30 | Univ Texas | تركيبات وطرق لتعديل نشاط ديهيدروجيناز بسلسلة قصيرة |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018746A1 (en) * | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
WO2004093803A2 (en) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Photochemotherapeutic compounds for use in treatment of pin1-associated states |
US20070065472A1 (en) * | 2005-06-28 | 2007-03-22 | L'oreal | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers |
US20070071699A1 (en) * | 2005-06-28 | 2007-03-29 | L'oreal | Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening |
WO2008109727A1 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US5807895A (en) | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
WO1996018400A1 (en) * | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
TR200000671T2 (tr) | 1997-09-09 | 2000-07-21 | The Procter & Gamble Company | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
EP1704141B1 (en) | 2004-01-05 | 2016-02-24 | Nicox S.A. | Prostaglandin nitrooxyderivatives |
FR2887443A1 (fr) * | 2005-06-28 | 2006-12-29 | Oreal | Utilisation de composes benzylidene-1,3-thiazolidine-2,4- diones pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/ou leur blanchement. |
US20070059265A1 (en) * | 2005-06-28 | 2007-03-15 | L'oreal | Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers |
-
2009
- 2009-12-30 WO PCT/KR2009/007995 patent/WO2010077101A2/ko active Application Filing
- 2009-12-30 EP EP09836422.7A patent/EP2383263B1/en not_active Not-in-force
- 2009-12-30 KR KR1020117017782A patent/KR101172638B1/ko active IP Right Grant
- 2009-12-30 US US13/142,924 patent/US8637558B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018746A1 (en) * | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
WO2004093803A2 (en) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Photochemotherapeutic compounds for use in treatment of pin1-associated states |
US20070065472A1 (en) * | 2005-06-28 | 2007-03-22 | L'oreal | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers |
US20070071699A1 (en) * | 2005-06-28 | 2007-03-29 | L'oreal | Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening |
WO2008109727A1 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
Non-Patent Citations (1)
Title |
---|
See also references of EP2383263A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2383263A4 (en) | 2012-08-22 |
US20110269954A1 (en) | 2011-11-03 |
EP2383263B1 (en) | 2014-04-16 |
WO2010077101A2 (ko) | 2010-07-08 |
WO2010077101A4 (ko) | 2011-01-13 |
KR20110107358A (ko) | 2011-09-30 |
US8637558B2 (en) | 2014-01-28 |
KR101172638B1 (ko) | 2012-08-08 |
EP2383263A2 (en) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010077101A3 (ko) | 신규한 티아졸리딘디온 유도체 및 그의 용도 | |
WO2010042163A3 (en) | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders | |
WO2010057101A3 (en) | Compounds useful as hiv blockers | |
WO2009064388A3 (en) | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders | |
WO2010001169A3 (en) | Chemical compounds 251 | |
WO2009153496A3 (fr) | Composes agonistes ppar, preparation et utilisations pour le traitement du diabete et/ou des dyslipidemies | |
WO2008006547A3 (en) | Pyrrolopyrimidines for pharmaceutical compositions | |
WO2009111700A3 (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
WO2008067119A3 (en) | Novel compounds | |
WO2006067165A3 (en) | Indolidone derivatives for the treatment or prevention of fibrotic diseases | |
WO2006099943A8 (de) | Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
WO2007097931A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
WO2008084223A3 (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
WO2006099941A8 (de) | Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
WO2009016410A3 (en) | Chemical compounds 831 | |
WO2006127379A3 (en) | Par2-modulating compounds and their use | |
WO2012046030A3 (en) | Phosphodiesterase inhibitors | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
WO2008149353A3 (en) | Telomerase activating compounds and methods of use thereof | |
WO2007022947A3 (de) | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
WO2011039735A3 (en) | Compounds with ddx3 inhibitory activity and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09836422 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13142924 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009836422 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117017782 Country of ref document: KR Kind code of ref document: A |